The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Health care utilization (HCU) by breast cancer (BC) and non-Hodgkin lymphoma (NHL) patients (pts) with chemotherapy (CT) induced febrile neutropenia (FN) in the Netherlands.
Hans Gelderblom
No relevant relationships to disclose
Pieternella Lugtenburg
No relevant relationships to disclose
J. W. R. Nortier
No relevant relationships to disclose
Myrthe van Herk-Sukel
Research Funding - Amgen
Djamila Issa
No relevant relationships to disclose
A. Jager
No relevant relationships to disclose
Margarita De La Orden
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Mirte van der Werf-Langenberg
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Leanne Houweling
Research Funding - Amgen
Floris Aart De Jong
Employment or Leadership Position - Amgen
Stock Ownership - Amgen